AstraZeneca's ambitious $80 billion revenue goal by 2030 hinges on oncology growth and successful new drug launches, but faces patent expiries and fierce competition. While current financials and ...
Huang Bin, the vice president of AstraZeneca China known as the "golden negotiator" for his extensive experience in pricing ...
AstraZeneca Plc’s playbook to break into the red-hot obesity market rests on improving upon existing medicines, offering competitive prices and leaning on its experience selling products in emerging ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has named Rick R. Suarez Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit. Suarez will lead the execution of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results